![\"Eli](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/shutterstock_1137479783.jpg\")
<\/p>\nThe agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.<\/p>\n
<\/p>\n
Eli Lilly and Company has agreed to acquire<\/a> Verve Therapeutics, Inc. in a deal set to advance genetic medicines for individuals at risk of cardiovascular disease.<\/p>\n This acquisition has a potential total value of up to approximately $1.3 billion. Verve\u2019s lead programme (VERVE-102) involves a potential first-in-class in vivo\u00a0gene editing therapy. The single-dose treatment targets the gene PCSK9, which according to the company, is associated with cholesterol levels and cardiovascular health.<\/p>\n Verve\u2019s pipeline involves gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) and could be suitable for individuals with heterozygous familial hypercholesterolemia (HeFH), the firm shared.<\/p>\n Dr Sekar Kathiresan, Verve\u2019s Co-founder and CEO highlighted that the company has, \u201cin just seven years\u2026progressed three in vivo\u00a0gene editing products, with two currently in the clinic.\u201d<\/p>\n Eli Lilly\u2019s commitment \u2013 addressing cardiovascular risk with a promising genetic medicine candidate<\/p>\n [VERVE-102] has the potential to be the first\u00a0in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment\u201d<\/p>\n VERVE-102 is being evaluated in a Phase\u00a0Ib\u00a0clinical trial<\/a>. The treatment \u201chas the potential to be the first\u00a0in vivo\u00a0gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,\u201d stated\u00a0Ruth Gimeno, Lilly group Vice President, Diabetes and Metabolic Research and Development.<\/p>\n The transaction is anticipated to close in Q3 of 2025, subject to customary closing conditions.<\/p>\n This latest deal follows Eli Lilly\u2019s announcement<\/a> last month highlighting its plans to acquire the biotech SiteOne Therapeutics, Inc. The agreement involves the Phase II-ready oral NaV1.8 inhibitor STC-004, being investigated to treat chronic pain. The medicine is anticipated to provide a next-generation treatment option for this condition. Shareholders of SiteOne will be eligible for a total of $1.0 billion.<\/p>\n Related topics<\/p>\n Big Pharma<\/a>, Biologics<\/a>, Biopharmaceuticals<\/a>, business news<\/a>, Clinical Development<\/a>, Clinical Trials<\/a>, Drug Development<\/a>, Gene therapy<\/a>, Industry Insight<\/a>, Mergers & Acquisitions<\/a>, Research & Development (R&D)<\/a>, Technology<\/a>, Therapeutics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that…\n","protected":false},"author":2,"featured_media":195058,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[267,70,16,15],"class_list":{"0":"post-195057","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114705767080815314","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/195057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=195057"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/195057\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/195058"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=195057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=195057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=195057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}